The pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
Progenics said that the new pre-filled syringes of Relistor will be available in 8mg and 12mg dosages and single-use vials of Relistor will continue to be available primarily for institutional use.
Progenics founder chief executive and chief science officer Paul Maddon said thatt he pre-filled syringe delivery system provides easier preparation of Relistor for advanced-illness patients with OIC, as well as their caregivers and Progenics is planning for the launch of Relistor in pre-filled syringes in the first half of 2011.
